The first interim analysis of the Phase 2 COCOON study met its primary endpoint, demonstrating that an easy-to-use and readily available regimen significantly reduced the frequency of moderate-to-severe skin and nail side effects (Grade… Read More
The Company has obtained shareholder approval for its proposed acquisition of Orion Health and its previously announced $55 million bought-deal financing. The Company also announced that a Schedule A Bank… Read More
VANCOUVER, BC — Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the successful achievement… Read More
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults… Read More
RESEARCH TRIANGLE PARK, NC – IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, announced a strategic collaboration with NVIDIA to help realize the… Read More
